Citius Pharmaceuticals Inc vs Schlumberger NV — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Schlumberger NV trades at $53.7 (market cap $78.96B). The key difference: Schlumberger NV is far larger — about 4215.7× Citius Pharmaceuticals Inc's market cap, and Schlumberger NV pays a 2.22% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | SLB | |
|---|---|---|
Market Cap | $18.73M | $78.96B |
Sector | Health | Energy |
52-Week High | $1.82 | $58.01 |
52-Week Low | $0.48 | $31.72 |
Enterprise Value | $14.95M | $87.68B |
Dividend Yield | — | 2.22% |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →